美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

美国抗疫概念

1,399.05

+5.730.41%

涨家数：10

跌家数：10

平家数：- -

市盈率：- -

高：1,407.77

开：1,394.31

低：1,388.60

收：1,393.32

数据加载中...

总览新闻资讯

Biontech Se6月4日成交额为1.73亿美元

阿斯利康6月4日成交额为2.65亿美元

再下一城！阿斯利康“度伐利尤单抗”国内获批新适应症

Insight数据库

独家-消息人士称，疾控中心官员辞去 COVID 疫苗委员会顾问职务

Corvus Pharmaceuticals, Inc.盘中异动股价大跌5.10%报3.91美元

Co-Diagnostics, Inc.盘中异动急速上涨5.75%报0.300美元

Ocugen, Inc.盘中异动早盘快速拉升5.10%报0.895美元

Ibio, Inc.盘中异动快速拉升5.36%

Aptos 6 月 30 日起自动迁移 APT 及其链上代币至 FA 标准

Aptos 6月30日起自动迁移APT及其链上代币至FA标准

阿斯利康英飞凡在华获批

辉瑞6月3日成交额为8.86亿美元

阿斯利康(AZN.US)重磅ADC新药“德曲妥珠单抗”3期临床结果公布

诺瓦瓦克斯医药6月3日成交额为4709.66万美元

莫德纳6月3日成交额为3.73亿美元

阿斯利康在2025年ASCO大会期间举办中国创新之夜，彰显"变革诊疗、推动共同健康"的坚定承诺

吉利德科学6月3日成交额为10.78亿美元

阿斯利康6月3日成交额为3.25亿美元

雅培6月3日成交额为7.88亿美元

ASCO 25：辉瑞Braftovi为结直肠癌患者带来“前所未有”的生存获益

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK4568/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美国抗疫概念","latestPrice":1399.0479,"timestamp":1749585599999,"preClose":1393.321,"halted":0,"volume":87121970,"delay":0,"changeRate":0.00411,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":5.726807,"latestTime":"06-10 16:00:00 EDT","open":1394.3126,"high":1407.7659,"low":1388.5961,"amount":3977866265.49153,"amplitude":0.013758,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1749600000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.684537,"peRate":21.902347,"turnoverRate":0.005615,"increases":10,"decrements":10,"flats":0,"marketCap":1153265233662.75,"floatMarketCap":1132979290728.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1407.7659,"amplitude":0.013758,"preClose":1393.321,"low":1388.5961,"pbRate":"3.684537","latestPrice":1399.0479,"volume":87121970,"delay":0,"open":1394.3126,"prevYearClose":1274.8187,"prevWeekClose":1387.2587,"prevMonthClose":1383.2164,"prevQuarterClose":1427.887,"fiveDayClose":1378.0182,"twentyDayClose":1347.5911,"sixtyDayClose":1428.6036,"secType":"PLATE","market":"US","turnoverRate":0.005615,"peRate":21.902347,"marketCap":1153265233662.75,"floatMarketCap":1132979290728.75,"timestamp":1749585599999,"nameCN":"美国抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541137310","title":"Biontech Se6月4日成交额为1.73亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541137310","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541137310?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 09:21","pubTimestamp":1749086488,"startTime":"0","endTime":"0","summary":"美东时间2025年6月4日，Biontech Se成交额为1.73亿美元，成交额较昨日减少54.49%，当日成交量为153.41万股。Biontech Se于2025年6月4日跌3.89%，报111.15美元，该股过去5个交易日涨13.96%，年初至今跌2.46%，过去60日涨5.5%。BioNTech与几家大型制药公司合作，包括罗氏、礼来、辉瑞、赛诺菲和Genmab。冠状病毒疫苗是其首个商业化产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605092139a6faf4d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605092139a6faf4d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4551","BNTX","BK4588","BK4548","BK4139","BK4585","BK4535"],"gpt_icon":1},{"id":"2541013201","title":"阿斯利康6月4日成交额为2.65亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541013201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541013201?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 09:18","pubTimestamp":1749086297,"startTime":"0","endTime":"0","summary":"美东时间2025年6月4日，阿斯利康成交额为2.65亿美元，成交额较昨日减少18.58%，当日成交量为362.11万股。阿斯利康于2025年6月4日涨1.64%，报73.0美元，该股过去5个交易日涨3.72%，年初至今涨13.23%，过去60日跌3.93%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-04|2.65亿|-18.58%|362.11万|#|2025-06-03|3.25亿|-29.22%|451.46万|#|2025-06-02|4.59亿|-21.09%|639.00万|#|2025-05-30|5.82亿|138.05%|803.43万|#|2025-05-29|2.44亿|-8.98%|346.09万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605091822a49a97e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605091822a49a97e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0109394709.USD","LU0889565916.HKD","LU2462157665.USD","LU2236285917.USD","BK4585","LU1829250122.USD","LU0320765992.SGD","LU2417539215.USD","LU2456880835.USD","AZN","BK4007","BK4568"],"gpt_icon":0},{"id":"2541097094","title":"再下一城！阿斯利康“度伐利尤单抗”国内获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2541097094","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541097094?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 07:46","pubTimestamp":1749080774,"startTime":"0","endTime":"0","summary":"6 月 4 日，阿斯利康宣布，英飞凡已获 NMPA 批准，作为单药用于在接受铂类药物为基础的放化疗后未出现疾病进展的局限期小细胞肺癌成人患者的治疗。预计，接受度伐利尤单抗单药治疗患者的三年 OS 率达到 57%，而安慰剂组为 48%。自首次获批以来，度伐利尤单抗的销售额一路上涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605075353a49a8300&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605075353a49a8300&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU2462157665.USD","BK4568","BK4588","LU0889565916.HKD","LU2236285917.USD","BK4585","BK4007","LU0320765992.SGD","LU2417539215.USD","AZN","LU1829250122.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2541109416","title":"独家-消息人士称，疾控中心官员辞去 COVID 疫苗委员会顾问职务","url":"https://stock-news.laohu8.com/highlight/detail?id=2541109416","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541109416?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 06:06","pubTimestamp":1749074804,"startTime":"0","endTime":"0","summary":"她在美国疾病控制和预防中心免疫实践咨询委员会的工作组中担任职务，共同负责收集有关演讲主题的信息。肯尼迪宣布这一消息两天后，疾控中心在网上公布了一份疫苗接种计划 ，称 COVID-19 疫苗仍然是 6 个月至 17 岁健康儿童在家长和医生同意的情况下接种疫苗的一种选择。此前，疾控中心曾建议为所有 6 个月及以上的儿童接种更新的 COVID 疫苗。两名消息人士称，帕纳吉奥塔科普洛斯没有说明她离职的具体原因。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nL3T3S71HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4585","BK4533","BK4501","BK4532","BK4551","BK4568","BK4548","BK4139","BK4588"],"gpt_icon":1},{"id":"2541959620","title":"Corvus Pharmaceuticals, Inc.盘中异动 股价大跌5.10%报3.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541959620","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541959620?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 02:58","pubTimestamp":1749063526,"startTime":"0","endTime":"0","summary":"北京时间2025年06月05日02时58分，Corvus Pharmaceuticals, Inc.股票出现异动，股价大幅下挫5.10%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.13%。其相关个股中，Cellectar Biosciences, Inc.、Hoth Therapeutics, Inc.、Lyell Immunopharma, Inc.涨幅较大，Nucana Plc、Cellectar Biosciences, Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为1651.05%、1292.85%、620.20%，振幅较大的相关个股有Cellectar Biosciences, Inc.、Hoth Therapeutics, Inc.、Lyell Immunopharma, Inc.，振幅分别为106.81%、82.62%、61.90%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506050258469771da45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506050258469771da45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRVS","BK4139","BK4568"],"gpt_icon":0},{"id":"2541098234","title":"Co-Diagnostics, Inc.盘中异动 急速上涨5.75%报0.300美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541098234","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541098234?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 01:14","pubTimestamp":1749057273,"startTime":"0","endTime":"0","summary":"北京时间2025年06月05日01时14分，Co-Diagnostics, Inc.股票出现异动，股价大幅上涨5.75%。截至发稿，该股报0.300美元/股，成交量7.3239万股，换手率0.22%，振幅5.82%。Co-Diagnostics, Inc.股票所在的医疗器械行业中，整体涨幅为0.21%。Co-Diagnostics, Inc.公司简介：Co-Diagnostics Inc是一家分子诊断公司。该公司还利用其专有技术为其 Co-Dx PCR 平台设计特定测试，并定位用于传染病以外应用的遗传标记。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605011433950ec7af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605011433950ec7af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CODX","BK4082","BK4568"],"gpt_icon":0},{"id":"2540062186","title":"Ocugen, Inc.盘中异动 早盘快速拉升5.10%报0.895美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540062186","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540062186?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 22:48","pubTimestamp":1749048515,"startTime":"0","endTime":"0","summary":"北京时间2025年06月04日22时48分，Ocugen, Inc.股票出现波动，股价快速拉升5.10%。截至发稿，该股报0.895美元/股，成交量112.216万股，换手率0.38%，振幅4.63%。Ocugen, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。Ocugen, Inc.公司简介：Ocugen Inc 公司专注于发现、开发和商业化新型基因和细胞疗法和疫苗，以改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506042248359771a08d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506042248359771a08d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OCGN","BK4568","BK4563"],"gpt_icon":0},{"id":"2540064945","title":"Ibio, Inc.盘中异动 快速拉升5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540064945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540064945?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 22:05","pubTimestamp":1749045909,"startTime":"0","endTime":"0","summary":"北京时间2025年06月04日22时05分，Ibio, Inc.股票出现异动，股价急速上涨5.36%。Ibio, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。其相关个股中，Cellectar Biosciences, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 涨幅较大，Nucana Plc、Cellectar Biosciences, Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为899.48%、641.66%、539.27%，振幅较大的相关个股有Cellectar Biosciences, Inc.、知临集团、Processa Pharmaceuticals, Inc.，振幅分别为106.81%、23.19%、21.85%。Ibio, Inc.公司简介：iBio公司是一家临床前阶段生物技术公司，利用人工智能的力量开发精准抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604220509950e9f48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604220509950e9f48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","IBIO"],"gpt_icon":0},{"id":"2540805582","title":"Aptos 6 月 30 日起自动迁移 APT 及其链上代币至 FA 标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2540805582","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540805582?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 17:01","pubTimestamp":1749027696,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7476478","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_live","symbols":["BK4568","BK4535","BK4086","BK4539","APT.USD.CC","BK4130","FA","APT.USD.HKCC","APT"],"gpt_icon":0},{"id":"2540053120","title":"Aptos 6月30日起自动迁移APT及其链上代币至FA标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2540053120","media":"Odaily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540053120?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 17:00","pubTimestamp":1749027623,"startTime":"0","endTime":"0","summary":"Odaily星球日报讯 Aptos 生态将于 2025 年 6 月 30 日起全面过渡至 Fungible Asset（FA）标准，取代旧版 Coin 框架。FA 标准于 2023 年底推出，具备更高的安全性、灵活性和可组合性，支持 DeFi、支付等高级用例。从 6 月 20 日起，新账户默认采用 FA 标准；6 月 30 日起，APT 代币余额将率先自动迁移，链上其他代币随后于 6 月 18 日至 22 日完成迁移，无需用户操作。此次升级由 Aptos Labs 推动，通过批量交易工具实现，Gas 由生态预付。\n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.odaily.news/newsflash/433359?source=share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"odaily_live","symbols":["FA","BK4539","BK4086","APT.USD.HKCC","APT","BK4535","APT.USD.CC","BK4568","BK4130"],"gpt_icon":0},{"id":"2540058931","title":"阿斯利康英飞凡在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2540058931","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540058931?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 16:59","pubTimestamp":1749027542,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2462157665.USD","BK4568","LU2236285917.USD","LU0320765992.SGD","BK4007","BK4588","LU0109394709.USD","BK4585","LU1829250122.USD","LU2456880835.USD","AZN","LU2417539215.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2540808038","title":"辉瑞6月3日成交额为8.86亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540808038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540808038?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 11:49","pubTimestamp":1749008974,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，辉瑞成交额为8.86亿美元，成交额较昨日增加24.29%，当日成交量为3788.71万股。辉瑞于2025年6月3日跌0.47%，报23.35美元，该股过去5个交易日跌1.1%，年初至今跌8.82%，过去60日跌10.98%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-03|8.86亿|24.29%|3788.71万|#|2025-06-02|7.13亿|-46.40%|3044.39万|#|2025-05-30|13.30亿|117.19%|5661.85万|#|2025-05-29|6.12亿|-28.44%|2621.01万|#|2025-05-28|8.56亿|0.45%|3673.72万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604114939a4993c2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604114939a4993c2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","LU0234572021.USD","BK4534","LU0306806265.USD","BK4568","BK4592","LU0289739699.SGD","LU0985481810.HKD","LU1057294990.SGD","SG9999002224.SGD","IE00BLSP4239.USD","SG9999002232.USD","SGXZ57979304.SGD","LU1023059063.AUD","LU1066051498.USD","IE00BBT3K403.USD","LU0321505439.SGD","IE000M9KFDE8.USD","SG9999013999.USD","LU0058720904.USD","IE00B19Z3581.USD","BK4533","LU1066053197.SGD","SG9999003800.SGD","PFE","LU0306807586.USD","LU0321505868.SGD","BK4581","LU0225284248.USD","SG9999001176.SGD","BK4588","LU1883839398.USD","BK4007","LU0868494617.USD","BK4599","IE00B19Z3B42.SGD","SG9999001176.USD","LU1894683348.USD","BK4585","LU0456855351.SGD","LU0170899867.USD","SG9999011175.SGD","BK4550","LU0225771236.USD","LU0122379950.USD","IE00BLSP4452.SGD","LU1894683264.USD"],"gpt_icon":1},{"id":"2540809430","title":"阿斯利康(AZN.US)重磅ADC新药“德曲妥珠单抗”3期临床结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2540809430","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540809430?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 11:37","pubTimestamp":1749008239,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康近日宣布，DESTINY-Breast09 3期研究积极结果显示，作为HER2阳性转移性乳腺癌患者的一线治疗，德曲妥珠单抗联合帕妥珠单抗，与当前一线标准治疗方案THP相比，在无进展生存期方面表现出高度统计学显著性和具有临床意义的改善。德曲妥珠单抗是一种靶向 HER2 的抗体偶联药物，由第一三共和阿斯利康共同开发和商业化。基于DESTINY-Breast03试验结果，德曲妥珠单抗已在全球80多个国家获批，用于HER2阳性乳腺癌患者的二线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1301024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","BK4007","BK4585","LU2236285917.USD","AZN","LU2462157665.USD","LU0109394709.USD","LU1829250122.USD","LU2417539215.USD","ADC","LU2456880835.USD","LU0889565916.HKD","BK4588","BK4080","LU0320765992.SGD","BK4568"],"gpt_icon":0},{"id":"2540080666","title":"诺瓦瓦克斯医药6月3日成交额为4709.66万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540080666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540080666?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 11:31","pubTimestamp":1749007913,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，诺瓦瓦克斯医药成交额为4709.66万美元，成交额较昨日减少4.85%，当日成交量为652.29万股。诺瓦瓦克斯医药于2025年6月3日涨2.69%，报7.26美元，该股过去5个交易日跌1.63%，年初至今跌9.7%，过去60日跌12.95%。公司认为其疫苗技术有潜力广泛应用于多种人类传染病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604113156a4993778&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604113156a4993778&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVAX","BK4588","BK4547","BK4568","BK4585","BK4139"],"gpt_icon":0},{"id":"2540630080","title":"莫德纳6月3日成交额为3.73亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540630080","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540630080?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 11:11","pubTimestamp":1749006665,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，莫德纳成交额为3.73亿美元，成交额较昨日增加7.11%，当日成交量为1343.99万股。莫德纳于2025年6月3日涨2.81%，报27.81美元，该股过去5个交易日涨3.92%，年初至今跌33.12%，过去60日跌21.9%。截至 2024年9月，莫德纳拥有处于临床试验中的40个mRNA开发候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604111111a6f98d72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604111111a6f98d72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","BK4501","BK4548","MRNA","BK4533","BK4568","BK4534","BK4532","BK4551"],"gpt_icon":0},{"id":"2540059079","title":"阿斯利康在2025年ASCO大会期间举办中国创新之夜，彰显\"变革诊疗、推动共同健康\"的坚定承诺","url":"https://stock-news.laohu8.com/highlight/detail?id=2540059079","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540059079?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 11:00","pubTimestamp":1749006000,"startTime":"0","endTime":"0","summary":"汇聚中外专家，共话科学突破与国际合作，加速癌症领域创新成果公平可及    上海 2025年6月4日 /美通社/ -- 在2025年美国临床肿瘤学会年会期间，阿斯利康成功举办\"中国创新之夜：变革诊疗，攻克肺癌，共同健康\"主题活动。各方围绕\"推动癌症诊疗变革\"展开一系列深度对话和专题讨论，并呼吁携手筑建“共同健康”的未来，进一步彰显了阿斯利康\"让癌症不再成为致死主因\"的雄心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4702768_ZH02768_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4007","BK4585","LU2236285917.USD","AZN","LU2462157665.USD","LU0109394709.USD","LU1829250122.USD","LU2417539215.USD","LU2456880835.USD","LU0889565916.HKD","BK4588","LU0320765992.SGD","BK4568"],"gpt_icon":0},{"id":"2540208107","title":"吉利德科学6月3日成交额为10.78亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540208107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540208107?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 09:59","pubTimestamp":1749002341,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，吉利德科学成交额为10.78亿美元，成交额较昨日减少0.73%，当日成交量为988.40万股。吉利德科学于2025年6月3日涨0.39%，报109.33美元，该股过去5个交易日涨0.22%，年初至今涨19.2%，过去60日跌6.23%。吉利德对Pharmasset的收购带来了丙型肝炎药物索磷布韦片的使用权，该药物也是仍为治疗标准的较新的联合方案的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604095902a4991927&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604095902a4991927&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU1430594728.SGD","LU1778281490.HKD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU1674673428.USD","LU1066053197.SGD","BK4585","LU0289739699.SGD","IE00B19Z3B42.SGD","LU2087621335.USD","BK4588","BK4578","IE00BSNM7G36.USD","LU0320765992.SGD","LU0058720904.USD","LU2468319806.SGD","LU1066051498.USD","BK4550","LU0823416689.USD","LU0109394709.USD","LU0234570918.USD","LU1571399168.USD","LU2089984988.USD","BK4566","BK4568","IE00B7SZLL34.SGD","BK4583","LU1674673691.USD","GILD","IE0002270589.USD","BK4532","LU1839511570.USD","IE00B3T34201.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2540108151","title":"阿斯利康6月3日成交额为3.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540108151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540108151?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 09:18","pubTimestamp":1748999891,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，阿斯利康成交额为3.25亿美元，成交额较昨日减少29.22%，当日成交量为451.46万股。阿斯利康于2025年6月3日跌0.15%，报71.82美元，该股过去5个交易日涨1.21%，年初至今涨11.4%，过去60日跌7.33%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-03|3.25亿|-29.22%|451.46万|#|2025-06-02|4.59亿|-21.09%|639.00万|#|2025-05-30|5.82亿|138.05%|803.43万|#|2025-05-29|2.44亿|-8.98%|346.09万|#|2025-05-28|2.69亿|-15.21%|382.08万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604091823a4990a36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604091823a4990a36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","LU2462157665.USD","BK4568","BK4588","LU0889565916.HKD","LU2236285917.USD","BK4585","BK4007","LU0320765992.SGD","LU2417539215.USD","AZN","LU1829250122.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2540608963","title":"雅培6月3日成交额为7.88亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2540608963","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540608963?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 09:15","pubTimestamp":1748999721,"startTime":"0","endTime":"0","summary":"美东时间2025年6月3日，雅培成交额为7.88亿美元，成交额较昨日增加32.48%，当日成交量为591.51万股。雅培于2025年6月3日涨0.1%，报133.71美元，该股过去5个交易日涨0.58%，年初至今涨19.38%，过去60日跌2.05%。雅培约 60% 的销售额来自美国以外地区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604091538a6f966e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604091538a6f966e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","IE00BJJMRZ35.SGD","LU1721429402.USD","SG9999004303.SGD","SG9999002232.USD","BK4566","BK4082","BK4588","BK4504","LU2112291526.USD","IE00B4R5TH58.HKD","LU1023059063.AUD","SG9999002224.SGD","IE00BFTCPJ56.SGD","LU0266013472.USD","BK4581","IE00BJT1NW94.SGD","LU1721429741.USD","LU1989763427.SGD","LU2133065610.SGD","IE0009355771.USD","BK4585","BK4533","LU0868494617.USD","LU2468319806.SGD","ABT","BK4592","BK4568","LU1989763690.USD","LU2089984988.USD","LU1691799644.USD","LU2237957902.USD","SGXZ23171101.USD","LU0170899867.USD","LU2237957811.SGD","LU0234572021.USD","IE0002141913.USD","LU1057294990.SGD","LU1914381329.SGD","LU0122379950.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2540570049","title":"ASCO 25：辉瑞Braftovi为结直肠癌患者带来“前所未有”的生存获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2540570049","media":"药事纵横","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540570049?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 06:02","pubTimestamp":1748988137,"startTime":"0","endTime":"0","summary":"在2025年美国临床肿瘤学会年度会议上，辉瑞公司公布了其激酶抑制剂Braftovi在治疗BRAF V600E突变型转移性结直肠癌方面取得了具有重大意义的成果，有望使其加速获批的Braftovi转化为全面批准。她补充道，研究结果表明，Braftovi治疗方案有望成为转移性结直肠癌领域“改变临床实践的新标准疗法”。接受Braftovi联合爱必妥和化疗治疗的患者，总生存期达到30.3个月，无进展生存期为12.8个月；而对照组患者的总生存期和无进展生存期分别为15.1个月和7.1个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604060442a498d5ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250604060442a498d5ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4533","LU1894683348.USD","SG9999002224.SGD","LU1057294990.SGD","LU0225284248.USD","LU1066051498.USD","SG9999013999.USD","LU0289739699.SGD","LU0234572021.USD","SG9999001176.SGD","BK4568","LU0058720904.USD","LU1894683264.USD","SGXZ57979304.SGD","SG9999011175.SGD","IE0002270589.USD","IE00BLSP4239.USD","LU0225771236.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4534","BK4581","LU0985481810.HKD","IE00B19Z3581.USD","BK4550","BK4585","LU0321505868.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU1883839398.USD","SG9999002232.USD","SG9999001176.USD","LU0122379950.USD","BK4599","BK4007","LU0306807586.USD","BK4592","LU0868494617.USD","PFE","BK4588","IE00BLSP4452.SGD","SG9999003800.SGD","LU0170899867.USD","LU0321505439.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0456855351.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":9,"pageCount":4,"totalSize":175,"code":"91000000","status":"200"}]}}